Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immune-oncology company focused on developing novel therapeutics to address resistance to cancer immunotherapy, which is a significant challenge in treating cancer patients [3][4]. - The company has recently acquired TBS-2025, a VISTA inhibiting monoclonal antibody asset, which is progressing into Phase 2 development for mutNPM1 relapsed/refractory acute myeloid leukemia (AML) [4]. Upcoming Event - TuHURA management will present at the 27th Annual H.C. Wainwright Global Investment Conference scheduled for September 8-10, 2025, in New York City [1][2]. - James Bianco, M.D., President and CEO of TuHURA, will provide an overview and is available for one-on-one meetings during the conference [2][7]. Product Development - The company is leveraging its Delta Opioid Receptor technology to create first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates aimed at targeting Myeloid Derived Suppressor Cells, which play a role in immune suppression within the tumor microenvironment [4].
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference